Medical devices, healthcare technology and the business of care
PMA approval · P210001

VENTANA MMR RxDx Panel

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics) · Decision date Aug 17, 2021

MEDTECHLEDGER EXPLANATIONP210001

What did the FDA approve?

The FDA database entry for P210001 records an approval decision dated August 17, 2021 for the VENTANA MMR RxDx Panel. The stated purpose is use as a companion diagnostic to identify patients with solid tumors whose DNA mismatch repair status is deficient, for potential treatment with JEMPERLI.

The entry classifies the device as an immunohistochemistry test for DNA mismatch repair protein assay under product code QNH, with Ventana Medical Systems, Inc. listed as the applicant. The source statement does not include supplement type or supplement reason fields, so no further detail about the regulatory pathway or scope of the original PMA is available in the supplied record.

FDA approval order statement

Approval for the Ventana MMR RxDx Panel as a CDx for identifying patients with solid tumors with dMMR status who may benefit from treatment with JEMPERLI.
Regulatory pathway
Original PMA
Clinical specialty
Pathology
Decision date
Aug 17, 2021

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P210001
Regulatory pathway
Premarket approval application
Product code
QNH
Decision code
APPR
Decision date
Aug 17, 2021
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Immunohistochemistry test, DNA mismatch repair (MMR) Protein assay.

Product code
QNH
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P210001 received

    Application receipt date recorded by FDA.

  2. P210001 · FDA decision

    APPR

Timeline entries are records held by MedtechLedger for P210001. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P210001

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)PMA supplementOct 8, 2026FDA

Explore the linked device profile

Other records with product code QNH

Product / regulatory recordCompanyPathwayDecision dateSource
Ventana Medical SystemsPMA supplementOct 8, 2026FDA
Agilent Technologies, Inc.PMA supplementSep 11, 2026FDA
Agilent Technologies, Inc.PMA approvalAug 15, 2025FDA
Ventana Medical SystemsPMA approvalApr 22, 2021FDA

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Ventana Medical Systems, Inc. (Roche Tissue Diagnostics)

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
1910 E. Innovation Park Dr., Tucson, AZ, 85755

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records